Day-10 to day-14 CA formation in Flt3-ITD+ and Flt3-ITD- AML blasts
AML patient . | Blast cells . | Day-10 to day-14 CAs, input 5 × 105 cells . | Day-35 CAFCs . |
---|---|---|---|
Flt3-ITD+ | |||
Patient 1 | PB | 98 ± 5 | 200+ |
Patient 2 | BM | 109 ± 14 | 200+ |
Patient 3 | BM | 200+ | 200+ |
Patient 4 | BM | 200+ | 200+ |
Asp 835+ | |||
Patient 1 | PB | 84 ± 3 | 200+ |
Flt3-ITD- | |||
Patient 1 | BM | 0 | 25 ± 1 |
Patient 2 | PB | 0 | 19 ± 2 |
Patient 3 | BM | 0 | 12 ± 2 |
Patient 4 | BM | 0 | 28 ± 4 |
Patient 5 | BM | 0 | 21 ± 3 |
AML patient . | Blast cells . | Day-10 to day-14 CAs, input 5 × 105 cells . | Day-35 CAFCs . |
---|---|---|---|
Flt3-ITD+ | |||
Patient 1 | PB | 98 ± 5 | 200+ |
Patient 2 | BM | 109 ± 14 | 200+ |
Patient 3 | BM | 200+ | 200+ |
Patient 4 | BM | 200+ | 200+ |
Asp 835+ | |||
Patient 1 | PB | 84 ± 3 | 200+ |
Flt3-ITD- | |||
Patient 1 | BM | 0 | 25 ± 1 |
Patient 2 | PB | 0 | 19 ± 2 |
Patient 3 | BM | 0 | 12 ± 2 |
Patient 4 | BM | 0 | 28 ± 4 |
Patient 5 | BM | 0 | 21 ± 3 |
PB indicates peripheral blood; BM, bone marrow.